Literature DB >> 11786305

Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression.

Johannes M H M Reul1, Florian Holsboer.   

Abstract

Corticotropin-releasing factor (CRF) and its related family members are implicated in stress-related disorders such as anxiety and depression. Recently, two new members of this neuropeptide family have been discovered in the brain: urocortin II (also known as stresscopin-related peptide) and urocortin III (also known as stresscopin). These urocortins are selective agonists for the CRF(2) receptor, show a distinct neuroanatomical localization and are involved in stress-coping responses such as anxiolysis. Thus, CRF, the urocortins and their receptors form an intricate network in the brain involved in the acute phase as well as the recovery phase of the stress response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11786305     DOI: 10.1016/s1471-4892(01)00117-5

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  122 in total

1.  Chronic anabolic androgenic steroid exposure alters corticotropin releasing factor expression and anxiety-like behaviors in the female mouse.

Authors:  Beth A Costine; Joseph G Oberlander; Matthew C Davis; Carlos A A Penatti; Donna M Porter; Robert N Leaton; Leslie P Henderson
Journal:  Psychoneuroendocrinology       Date:  2010-05-26       Impact factor: 4.905

2.  Perifornical Urocortin-3 mediates the link between stress-induced anxiety and energy homeostasis.

Authors:  Yael Kuperman; Orna Issler; Limor Regev; Ifat Musseri; Inbal Navon; Adi Neufeld-Cohen; Shosh Gil; Alon Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

Review 3.  Mad men, women and steroid cocktails: a review of the impact of sex and other factors on anabolic androgenic steroids effects on affective behaviors.

Authors:  Marie M Onakomaiya; Leslie P Henderson
Journal:  Psychopharmacology (Berl)       Date:  2016-01-12       Impact factor: 4.530

Review 4.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

5.  Brain Fos expression during 48 h after cisplatin treatment: neural pathways for acute and delayed visceral sickness.

Authors:  Charles C Horn; Marc Ciucci; Arun Chaudhury
Journal:  Auton Neurosci       Date:  2006-11-07       Impact factor: 3.145

6.  Effects of social isolation on mRNA expression for corticotrophin-releasing hormone receptors in prairie voles.

Authors:  Hossein Pournajafi-Nazarloo; Leila Partoo; Jason Yee; Jennifer Stevenson; Lisa Sanzenbacher; William Kenkel; Seyed Ramezan Mohsenpour; Kozo Hashimoto; C Sue Carter
Journal:  Psychoneuroendocrinology       Date:  2010-11-20       Impact factor: 4.905

7.  The effect of long-term ovariectomy on midbrain stress systems in free ranging macaques.

Authors:  Cynthia L Bethea; Arubala P Reddy
Journal:  Brain Res       Date:  2012-10-01       Impact factor: 3.252

Review 8.  The CRF system, stress, depression and anxiety-insights from human genetic studies.

Authors:  E B Binder; C B Nemeroff
Journal:  Mol Psychiatry       Date:  2009-12-15       Impact factor: 15.992

9.  Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice.

Authors:  Victoria B Risbrough; Richard L Hauger; Mary Ann Pelleymounter; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

Review 10.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.